Liquid Biopsy in Cancer Diagnostics Market Summary
The liquid biopsy in cancer diagnostics market was valued at nearly USD 7.64 billion in 2025 and is expected to reach USD 19.24 billion by 2034, growing at a CAGR of approximately 16.64% during the forecast period from 2026 to 2034. This growth is largely driven by the rising incidence of various cancers, growing demand for minimally invasive diagnostic procedures, increasing adoption of precision medicine, and continuous technical innovation in product development. North America is expected to dominate the overall market, while Asia-Pacific is projected to be the fastest-growing region. The market structure is currently described as moderately consolidated.
Explore DelveInsight’s Full Coverage on the Liquid Biopsy in Cancer Diagnostics Market
Liquid Biopsy in Cancer Diagnostics Overview
Liquid biopsy is a non-invasive diagnostic approach that analyzes biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating free DNA, and exosomes from patient samples including blood, urine, and saliva. It serves as an alternative to conventional surgical or tissue biopsies, reducing patient discomfort, complications, and cost while enabling frequent, repeatable sampling. This allows real-time monitoring of tumor evolution, treatment response, and the emergence of resistance mutations, supporting its growing role across screening, diagnosis, prognosis, treatment selection, and minimal residual disease (MRD) monitoring.
Recent Developmental Activities in the Liquid Biopsy in Cancer Diagnostics Market
- In June 2026, BioMark Diagnostics Inc. announced that the USPTO issued a Notice of Allowance for its proprietary urine-based lung cancer detection patent application, covering treatment monitoring, high-risk screening, and therapeutic efficacy assessment
- In June 2026, Hummingbird Diagnostics GmbH announced plans to showcase new data on its liquid biopsy RNA biomarkers in lung cancer at the EACR Congress in Budapest
- In May 2026, Avant Genomics secured over USD 3 million in funding to advance its automated liquid biopsy sample preparation platform
- In April 2026, CareDx Inc. signed a definitive agreement to acquire Naveris, a precision oncology diagnostics company focused on blood-based surveillance of viral-driven cancers, in a deal valued at up to USD 260 million including milestone payments
- In April 2026, TCM Biotech received FDA Breakthrough Device Designation for CatCHimera, its liquid biopsy platform for MRD detection in hepatocellular carcinoma
- In April 2026, Johnson & Johnson launched an initiative in the United Arab Emirates to fund liquid biopsy testing access for eligible metastatic NSCLC patients, utilizing Guardant Health’s genomic testing platform
- In April 2026, PanGIA Biotech announced publication of a peer-reviewed clinical study validating its urine-based, machine learning-powered liquid biopsy platform for prostate cancer detection
Liquid Biopsy in Cancer Diagnostics Market Dynamics
Key growth drivers include:
- Rising global cancer burden, with increasing incidence of solid tumors such as lung, breast, colorectal, and prostate cancers expanding demand for repeatable, non-invasive diagnostic tools
- Shift toward minimally invasive diagnostics that reduce patient discomfort, complications, and cost compared to surgical or tissue biopsy
- Advancements in genomic technologies such as next-generation sequencing (NGS) and digital PCR, improving test sensitivity and specificity for detecting ctDNA, CTCs, and exosomes
- Growing use in personalized and precision oncology, supporting molecular profiling and detection of actionable mutations such as EGFR, ALK, KRAS, and BRAF
- Increasing adoption in treatment monitoring, particularly for minimal residual disease detection, relapse prediction, and identifying drug resistance
- Expanding regulatory approvals and reimbursement coverage, including FDA-approved companion diagnostics and improving reimbursement frameworks across the US, EU, and APAC
- Integration into clinical trials and drug development for patient selection and biomarker-based stratification
- Rising investments and collaborations among biotech companies, research institutions, and diagnostics firms
- Rapid growth of multi-cancer early detection (MCED) tests based on DNA methylation, cfDNA patterns, and proteomics
- Growing adoption of AI and bioinformatics to improve biomarker detection, variant calling, and data interpretation
However, the risk of false results due to procedural limitations and lack of standardization of procedures remains a key challenge restraining market growth.
Liquid Biopsy in Cancer Diagnostics Market Players
Liquid Biopsy in Cancer Diagnostics companies include:
- Myriad Genetics Inc
- Exact Sciences Corporation
- Biocartis
- Sysmex Corporation
- Thermo Fisher Scientific Inc
- Biocept Inc
- Agilent Technologies Inc
- MDx Health
- Neogenomics Laboratories
- F. Hoffman La Roche Ltd
- Guardant Health
- Bio-Techne
- Illumina Inc
- QIAGEN
- Lucence Health Inc
- Personal Gemone Diagnostics Inc
- SAGA Diagnostics
- Agena Bioscience Inc
- The Menarini Group
- MiRXES Pte Ltd
- And Others.
Liquid Biopsy in Cancer Diagnostics Market Segment Analysis
The market is segmented by product type (instruments and reagents & kits, and services), sample type (blood, urine, and saliva), biomarker type (circulating tumor cells, circulating tumor DNA, circulating free DNA, and others), cancer type (lung, breast, colon, and others), technique (polymerase chain reaction and next-generation sequencing), end-user (hospitals, diagnostic centers, and others), and geography.
In the type segment, the services category accounted for 73% of market revenue share in 2024, reflecting the broad scope of services offered by companies, ranging from sample collection to NGS analysis. Companies such as BARD1 offer sample preparation platforms, while Biodesix provides blood-based, multi-technology diagnostic research services supporting biopharmaceutical clients. Given this wide application area, the services category is expected to maintain a formidable share going forward.
Liquid Biopsy in Cancer Diagnostics Regional Analysis
North America is expected to account for the dominant share of the global market, supported by the increasing prevalence of cancers, strong focus on oncology research, supportive government policies, and a conducive environment for product development and launches.
Among North American countries, the United States accounted for 87% of regional revenue share in 2025, driven by the high prevalence of cancers, substantial healthcare and research investment, and a supportive FDA regulatory environment, including breakthrough device designations awarded to technologies such as Inviata Limited’s minimal residual disease test and Bluestar Genomics’ pancreatic cancer detection test. Reimbursement coverage, such as CMS National Coverage Policy for InVisionFirst, has further supported adoption.
Rising prevalence of lifestyle-related risk factors, including obesity and an aging population, is also contributing to cancer incidence and, in turn, liquid biopsy demand across the region, including in Mexico.
Liquid Biopsy in Cancer Diagnostics Market Outlook
The market is projected to grow from USD 7.64 billion in 2025 to USD 19.24 billion by 2034, at a CAGR of approximately 16.64% between 2026 and 2034, with the study period spanning 2023 to 2034 and 2025 as the base year.
Download the Liquid Biopsy in Cancer Diagnostics market report for in-depth insights on segment and regional analysis
Conclusion
The Liquid Biopsy in Cancer Diagnostics market is set for substantial growth through 2034, propelled by the rising global cancer burden, the shift toward minimally invasive diagnostics, and continued advancements in genomic and AI-driven technologies. North America is expected to retain its dominant position, while the services segment continues to account for the largest revenue share. Expanding regulatory approvals, growing reimbursement support, and rising integration of liquid biopsy into precision oncology and clinical trials are further strengthening market momentum. With ongoing product launches, strategic acquisitions, and ongoing innovation in multi-cancer early detection and MRD monitoring, the liquid biopsy market is poised to play an increasingly central role in the future of cancer diagnostics and management.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
